53 results
8-K
EX-10.1
MIRA
Mira Pharmaceuticals Inc
28 Jun 24
Departure of Directors or Certain Officers
5:00pm
appoints the Chief Executive Officer of the Company as attorney-in-fact to execute documents on Employee’s behalf for this purpose upon Employee’s
10-K
2023 FY
EX-4.4
MIRA
Mira Pharmaceuticals Inc
1 Apr 24
Annual report
7:00am
or omission which was committed in bad faith or with malicious purpose or in a manner exhibiting wanton and willful disregard of human rights, safety
10-K
2023 FY
MIRA
Mira Pharmaceuticals Inc
1 Apr 24
Annual report
7:00am
exposed to a single dose and then multiple doses of the product candidate. The primary purpose of these clinical trials is to assess the metabolism … under the Securities Act.
The audit committee’s main purpose is to oversee our corporate accounting and financial reporting process. Our audit
8-K
MIRA
Mira Pharmaceuticals Inc
7 Mar 24
Other Events
4:45pm
The purpose of this Current Report on Form 8-K of Mira Pharmaceuticals, Inc. (the “Company”) is to provide updated information regarding the Company’s
8-K
EX-10.1
frer07
20 Nov 23
MIRA Pharmaceuticals Announces Exclusive Licensing Agreement for Oral Ketamine Analog, Ketamir-2
8:10am
8-K
q1m9c
20 Nov 23
MIRA Pharmaceuticals Announces Exclusive Licensing Agreement for Oral Ketamine Analog, Ketamir-2
8:10am
8-K
EX-10.2
7plodv6j ua5r
20 Nov 23
MIRA Pharmaceuticals Announces Exclusive Licensing Agreement for Oral Ketamine Analog, Ketamir-2
8:10am
8-K
EX-10.3
uycj0kcpryehbf7 g3a
20 Nov 23
MIRA Pharmaceuticals Announces Exclusive Licensing Agreement for Oral Ketamine Analog, Ketamir-2
8:10am
8-K
EX-1.1
1h1xlern5e8rfm
7 Aug 23
MIRA Pharmaceuticals, Inc. Announces Pricing of $8.9 Million Initial
5:14pm
8-K
EX-4.1
yj0eq3q6hvr4egpq
7 Aug 23
MIRA Pharmaceuticals, Inc. Announces Pricing of $8.9 Million Initial
5:14pm
424B4
9an1g457
4 Aug 23
Prospectus supplement with pricing info
1:01pm
424B1
uh3dgcrlf 8s7ljb
4 Aug 23
Prospectus with pricing info
12:59pm